Compare MasTec Inc (MTZ) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Novavax Inc — how do they compare? MasTec Inc trades at $348.86 (market cap $26.60B), while Novavax Inc trades at $8.11 (market cap $1.30B). The key difference: MasTec Inc is far larger — about 20.5× Novavax Inc's market cap, and MasTec Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| MTZ | NVAX | |
|---|---|---|
Market Cap | $26.60B | $1.30B |
Sector | Technology | Health |
52-Week High | $437.51 | $11.19 |
52-Week Low | $172.51 | $6.22 |
Enterprise Value | $29.34B | $800.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $336.61, up 2.13% today, amid strong analyst sentiment with 32 of 36 analysts rating it a Buy. The stock shows robust fundamentals with Q1 2026 EPS beating estimates by 40.6% and a record $20.3 billion backlog. Recent $1.65 billion acquisition of The Superior Group enhances data center infrastructure capabilities, positioning MTZ for AI-driven power demand growth. Technical indicators are bearish overall, with the stock trading near pivot point resistance at $338.
Outlook remains positive given earnings momentum and strategic expansion, though high P/E of 58.95 poses valuation risk. Upside to consensus price target of $497.45 offers 47.8% potential, but investors face execution risks from integration and debt-funded acquisitions. Revenue growth to $15.3 billion in 2026 supports bullish thesis if margins hold.
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
